- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06178354
Focal Ablation With Focal Cryotherapy or HIFU for the Treatment of Men With Localized Prostate Cancer
A Pragmatic Phase 2 Study of Focal Ablation (Focal Cryotherapy or High Intensity Frequency Ultrasound) in Men With Clinically Localized Prostate Cancer
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
PRIMARY OBJECTIVE:
I. To determine the efficacy of focal therapy for treatment of prostate cancer.
SECONDARY OBJECTIVES:
I. Patient reported urinary, sexual function and quality of life (QOL) at 1 year.
II. To assess safety.
OUTLINE:
Patients undergo focal cryotherapy or high intensity focused ultrasound on study.
After completion of study treatment, patients are followed up at 7-14 days and periodically for up to 3 years.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95817
- Recruiting
- University of California Davis Comprehensive Cancer Center
-
Principal Investigator:
- Marc Dall'Era
-
Contact:
- Marc Dall'Era
- Phone Number: 916-734-3772
- Email: mdallera@ucdavis.edu
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Ability to understand and willingness to sign an informed consent form
- Clinically localized grade group 1, 2, or 3 prostate cancer and unilateral magnetic resonance imaging (MRI) visible lesion(s). Up to 3 lesions will be allowed for focal treatment
- Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1 (Karnofsky ≥ 70%)
- Patients ≥ 18 years of age at time of consent
- Life expectancy ≥ 5 years
- Ability and stated willingness to adhere to the study visit schedule and other protocol procedures/requirements for the duration of the study
Exclusion Criteria:
- Nodal or distant metastases
- Prior treatment for prostate cancer
- Anticipated treatment with any cancer intervention, including radiation, hormonal therapy or surgery ≤ 6 months prior to focal therapy in this study
- Known contraindications to general anesthesia
- Uncorrectable coagulopathy
- Significant active cardiac disease within the previous 6 months including: New York Heart Association (NYHA) class 4 congestive heart failure (CHF), unstable angina, or myocardial infarction
- Any condition that would prohibit the understanding or rendering of informed consent
- Any condition that in the opinion of the investigator would interfere with the participant's safety or compliance while on trial
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment (cryosurgery, high intensity focused ultrasound)
Patients undergo focal cryotherapy or high intensity focused ultrasound on study.
|
Ancillary studies
Undergo focal cryotherapy ablation
Other Names:
Undergo high intensity frequency ultrasound ablation
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Pathologic outcome on surveillance prostate biopsy
Time Frame: At year 1 and 3
|
Confidence intervals for the pathologic response rate will be calculated using the Wilson score method.
Pathologic response rate will be analyzed by baseline clinical and molecular characteristics using univariable and multivariable logistic regression.
|
At year 1 and 3
|
Proportion of participants who go onto whole gland salvage treatment
Time Frame: At 3 years
|
Will be estimated using the Kaplan-Meier method.
|
At 3 years
|
Salvage whole gland treatment free survival
Time Frame: At 3 years
|
Will be analyzed by baseline clinical and molecular characteristics using univariable and multivariable Cox proportional hazards models.
|
At 3 years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Urinary function
Time Frame: At 1 year
|
Scores from Expanded Prostate Cancer Index Composite (EPIC-26) prostate cancer questionnaire will be used to assess urinary function.
|
At 1 year
|
Sexual function
Time Frame: At 1 year
|
Scores from EPIC-26 prostate cancer questionnaire will be used to assess sexual function.
|
At 1 year
|
Quality of life
Time Frame: At 1 year
|
Scores from EPIC-26 prostate cancer questionnaire will be used to assess quality of life.
|
At 1 year
|
Adverse events
Time Frame: Up to end of treatment visit, approximately 7-14 days after treatment
|
Number of participants experiencing treatment-related AEs, classified by severity and grade.
|
Up to end of treatment visit, approximately 7-14 days after treatment
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Marc Dall'Era, University of California, Davis
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimated)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- UCDCC306 (Other Identifier: University of California Davis Comprehensive Cancer Center)
- P30CA093373 (U.S. NIH Grant/Contract)
- NCI-2023-09811 (Registry Identifier: CTRP (Clinical Trial Reporting Program))
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Localized Prostate Carcinoma
-
University of California, San FranciscoNot yet recruitingProstate Adenocarcinoma | Localized Prostate CarcinomaUnited States
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Localized Prostate CarcinomaUnited States
-
CHU de Quebec-Universite LavalRecruitingProstate Cancer | Localized Prostate Carcinoma | Radiotherapy Side Effect | Radiotherapy | Brachytherapy | HypofractionationCanada
-
M.D. Anderson Cancer CenterRecruitingBiochemically Recurrent Prostate Carcinoma | Prostate Adenocarcinoma | Localized Prostate CarcinomaUnited States
-
Shanghai Changzheng HospitalShanghai Zhongshan Hospital; The First Affiliated Hospital of Guangzhou Medical... and other collaboratorsRecruitingProstate Adenocarcinoma | Localized Prostate CarcinomaChina
-
Consorci Sanitari de TerrassaCompletedLocalized Prostate Carcinoma | Predictive Cancer Model
-
Turku University HospitalRecruitingProstate Cancer | Localized Prostate Carcinoma | Intermediate Risk Prostate Cancer | Castration-Naive Prostate CancerFinland
-
National Cancer Institute (NCI)RecruitingProstate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8United States
-
Mayo ClinicRecruitingProstate Cancer | Prostate Adenocarcinoma | Localized Prostate Carcinoma | Stage I Prostate Cancer AJCC v8 | Stage II Prostate Cancer AJCC v8United States
-
NanOlogy, LLCUS Biotest, Inc.TerminatedUrogenital Neoplasms | Genital Neoplasms, Male | Prostate Cancer | Prostate Adenocarcinoma | Prostatic Neoplasm | Localized Cancer | Prostate Cancer AdenocarcinomaUnited States
Clinical Trials on Survey Administration
-
Rutgers, The State University of New JerseyNational Cancer Institute (NCI)TerminatedHealth Status UnknownUnited States
-
Centre Oscar LambretCentre Hospitalier Universitaire de BesanconTerminated
-
Boston UniversityNational Heart, Lung, and Blood Institute (NHLBI)Completed
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI)RecruitingAcute Lymphoblastic LeukemiaUnited States
-
M.D. Anderson Cancer CenterRecruitingHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
University of Southern CaliforniaNational Cancer Institute (NCI)TerminatedAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic... and other conditionsUnited States
-
M.D. Anderson Cancer CenterActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Advanced Malignant Solid Neoplasm | Locally Advanced Malignant Solid Neoplasm | Recurrent Malignant Solid Neoplasm | Metastatic Malignant Solid Neoplasm | COVID-19 Infection | Recurrent Hematologic MalignancyUnited States
-
Thomas Jefferson UniversityNational Cancer Institute (NCI)CompletedHematopoietic and Lymphoid Cell Neoplasm | Malignant Solid NeoplasmUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedPancreatic Adenocarcinoma | Gastric Adenocarcinoma | Pancreatic Neuroendocrine CarcinomaUnited States
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)CompletedMalignant NeoplasmUnited States